Streptococcus Patents (Class 514/2.6)
-
Publication number: 20140142029Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2013Publication date: May 22, 2014Applicant: RQx Pharmaceuticals, Inc.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, David CAMPBELL, Prasuna PARASELLI
-
Publication number: 20140142028Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.Type: ApplicationFiled: February 15, 2013Publication date: May 22, 2014Applicant: The Regents of the University of CaliforniaInventor: The Regents of the University of California
-
Publication number: 20140128314Abstract: Provided is a bacteriocin that is capable of being easily mass-produced, has high antimicrobial activity even at low concentration, has a wide antimicrobial spectrum, and is less likely to produce resistant microorganisms. The bacteriocin has the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING, or has the same amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING except that one or several amino acids are deleted, substituted, inserted and/or added, wherein the amino acid sequence provides antimicrobial activity and the isoelectric point is not less than 12.Type: ApplicationFiled: February 9, 2012Publication date: May 8, 2014Applicant: HIROSHIMA UNIVERSITYInventor: Hiroki Nikawa
-
Patent number: 8680058Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.Type: GrantFiled: November 2, 2010Date of Patent: March 25, 2014Assignees: The Regents of the University of California, C3 Jian, Inc.Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
-
Patent number: 8648047Abstract: Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oligomers and derivatives of these oligomers, hyaluronan binding proteins, antibodies specific for hyaluronan receptors, hyaluronan mimetics, inhibitors of hyaluronan synthesis, and stimulators of hyaluronan degradation.Type: GrantFiled: December 28, 2011Date of Patent: February 11, 2014Assignee: Tufts UniversityInventors: Bryan P. Toole, Suniti Misra, Shibnath Ghatak
-
Publication number: 20140037634Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: May 24, 2013Publication date: February 6, 2014Inventors: Randolph J. Noelle, Li Wang
-
Patent number: 8633154Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: GrantFiled: March 6, 2013Date of Patent: January 21, 2014Assignee: Arizona Board of Regents, a body corporate of the State of Arizona Acting for and on behalf of Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130345120Abstract: The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.Type: ApplicationFiled: March 9, 2012Publication date: December 26, 2013Applicant: Glaxosmithkline LLCInventors: Kelly M. Aubart, Andrew B. Benowitz, Yuhong Fang, James Hoffman, Joseph M. Karpinski, Andrew Nicholson Knox, Xiangmin Liao, Donghui Qin, Dongchuan Shi, Jared T. Spletstoser
-
Patent number: 8609608Abstract: This invention provides novel antimicrobial peptides that are effective to inhibit growth and/or proliferation of various gram positive bacteria. In particular, the peptides are effective against Streptococcus mutans a common oral pathogen and the causative agent of dental caries.Type: GrantFiled: March 24, 2010Date of Patent: December 17, 2013Assignees: C3 Jian, Inc., The Regents of the University of CaliforniaInventors: Jian He, Randal H. Eckert, Fengxia Qi, Maxwell H. Anderson, Wenyuan Shi
-
Patent number: 8575093Abstract: A method of preventing and/or treating S. pneumoniae infection in mammalian subjects, wherein said method comprises administering to said subjects a composition comprising one or more agents that are capable of inhibiting the binding of the S. pneumoniae cell wall protein FBA to the respiratory tract cells of said subject.Type: GrantFiled: September 29, 2008Date of Patent: November 5, 2013Assignees: Ben-Gurion University of the Negev Research and Development Authority, Mor Research Applications Ltd.Inventors: Yaffa Mizrachi Nebenzahl, Ron Dagan
-
Publication number: 20130281360Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.Type: ApplicationFiled: August 31, 2011Publication date: October 24, 2013Applicant: The Scipps Research InstituteInventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
-
THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE
Publication number: 20130274174Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Kenneth F. Bartizal, Jeffrey B. Locke, Karen Joy Shaw, Philippe G. Prokocimer -
Publication number: 20130253382Abstract: Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Inventors: RODOLFO ALARCON, Amy K. McNulty
-
Publication number: 20130231276Abstract: Bacterial multidrug resistance is attenuated in a subject by administering an aminoacyl-tRNA synthetase inhibitor and an antibacterial agent to the subject, wherein the aminoacyl-tRNA synthetase inhibitor is distinct from the antibacterial agent.Type: ApplicationFiled: April 12, 2013Publication date: September 5, 2013Applicant: Brown UniversityInventors: Jason K. Sello, James J. Vecchione
-
Publication number: 20130217619Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: RQX PHARMACEUTICALS, INC.Inventor: RQX Pharmaceuticals, Inc.
-
Structural and mechanistic basis for novel compound biosynthesis using the 4-electron hexose oxidase
Patent number: 8507427Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: GrantFiled: October 1, 2010Date of Patent: August 13, 2013Assignee: Academia SinicaInventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu -
Publication number: 20130184201Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: ApplicationFiled: March 6, 2013Publication date: July 18, 2013Applicants: Arizona State UniversityInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130184200Abstract: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.Type: ApplicationFiled: July 23, 2012Publication date: July 18, 2013Inventors: Martina Ochs, Roger Brooks, Robert Charlebois, Jeremy Yethon
-
Publication number: 20130172237Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.Type: ApplicationFiled: February 11, 2013Publication date: July 4, 2013Applicant: TARGANTA THERAPEUTICS CORP.Inventor: Targanta Therapeutics Corp.
-
Patent number: 8475809Abstract: The present invention provides an immunogenic composition comprising one or more Streptococcus uberis sortase-anchored surface proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.Type: GrantFiled: October 6, 2009Date of Patent: July 2, 2013Assignee: The University of NottinghamInventor: James Leigh
-
Publication number: 20130150286Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.Type: ApplicationFiled: June 25, 2010Publication date: June 13, 2013Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
-
Patent number: 8435938Abstract: The new pure vancomycin hydrochloride substantially free of impurities known in commercially available products is described. The term “substantially free of impurities” designates a purity of vancomycin hydrochloride between about 97% and about 99%, particularly between about 98% and about 99%, preferably about 99%, as determined by HPLC analytical method as directed in U.S.P., NF 27th revision, 22 (2004). The new pure vancomycin hydrochloride (vancomycin B hydrochloride) contains less than 0.7% of total impurities, namely, only one impurity exceeds 0.3%. The new process for the purification of crude vancomycin by displacement chromatography is described by which the desired pure antibiotic according to the present invention is produced, based on the finding that high purity of the vancomycin hydrochloride is obtained using low selected pH values of the mobile phase between 3.9 and 4.2.Type: GrantFiled: December 5, 2005Date of Patent: May 7, 2013Assignee: Lek Pharmaceuticals d.d.Inventors: Rok Grahek, Andrej Bastarda
-
Publication number: 20130108575Abstract: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.Type: ApplicationFiled: October 16, 2012Publication date: May 2, 2013Applicant: C3 JIAN, INC.Inventor: C3 Jian, Inc.
-
THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE
Publication number: 20130102523Abstract: A therapeutic combination comprises an antibacterially effective amount of daptomycin, and an amount of protein synthesis inhibitor antibiotic effective to prevent the development of daptomycin non-susceptibility in bacteria. Related combination therapies and methods are also included.Type: ApplicationFiled: October 19, 2012Publication date: April 25, 2013Applicant: TRIUS THERAPEUTICS, INC.Inventor: Trius Therapeutics, Inc. -
Patent number: 8420592Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.Type: GrantFiled: August 29, 2009Date of Patent: April 16, 2013Assignee: The Medicines CompanyInventors: Dario Lehoux, Thomas R. Parr, Gregory Moeck, Pierre Etienne
-
Patent number: 8415294Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.Type: GrantFiled: June 5, 2008Date of Patent: April 9, 2013Assignee: Arizona Board of RegentsInventors: George R. Pettit, Rui Tan, Robin K. Pettit
-
Publication number: 20130071416Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS)Type: ApplicationFiled: April 1, 2011Publication date: March 21, 2013Applicant: NOVARTIS AGInventors: Guido Grandi, Domenico Maione, Cira Daniela Rinaudo
-
Publication number: 20130052182Abstract: The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Applicant: LYSANDO AGInventor: Stefan Miller
-
Patent number: 8343483Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.Type: GrantFiled: October 15, 2008Date of Patent: January 1, 2013Assignee: Biogaia ABInventors: Bo Mollstam, Eamonn Connolly
-
Publication number: 20120328632Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: December 21, 2011Publication date: December 27, 2012Applicant: Genentech, Inc.Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Publication number: 20120316103Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: ApplicationFiled: August 22, 2012Publication date: December 13, 2012Applicant: NOVABIOTICS LIMITEDInventor: Deborah O'NEIL
-
Publication number: 20120309676Abstract: Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.Type: ApplicationFiled: February 1, 2011Publication date: December 6, 2012Inventors: Sjoerd Nicolaas Wadman, Antony Nicholas Appleyard
-
Publication number: 20120308638Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Inventors: Mathew Upton, Stephanie Sandiford
-
Patent number: 8324354Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.Type: GrantFiled: October 31, 2007Date of Patent: December 4, 2012Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Patent number: 8299020Abstract: The present invention relates to a novel Paenibacillus polymyxa strain, OSY-DF, and its bioactive mutants. Also provided is a method for using a novel antimicrobial peptide, paenibacillin, isolated from the bacterial strain OSY-DF, and its bioactive variants or fragments. The invention also relates to antimicrobial compositions containing same and methods of their use.Type: GrantFiled: September 28, 2007Date of Patent: October 30, 2012Assignee: The Ohio State University Research FoundationInventors: Ahmed El-Meleigy Yousef, Zengguo He, Chunhua Yuan, Liwen Zhang, Duygu Kisla
-
Publication number: 20120207778Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences.Type: ApplicationFiled: February 16, 2012Publication date: August 16, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: John Telford, Vega Masignani, Immaculada Margarit Y Ros, Guido Grandi, Claire Fraser, Hervé Tettelin
-
Publication number: 20120189682Abstract: The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is generally a dispersant or an anti-adhesive agent. There is also provided the use of the product in the treatment of a microbial infection.Type: ApplicationFiled: March 31, 2010Publication date: July 26, 2012Applicant: Novabiotics LimitedInventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
-
Publication number: 20120172289Abstract: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.Type: ApplicationFiled: December 28, 2011Publication date: July 5, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Bengang Xing, Tingting Jiang, Roushen Liew
-
Publication number: 20120165276Abstract: Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.Type: ApplicationFiled: May 6, 2008Publication date: June 28, 2012Applicant: Mpex Pharmaceuticals, Inc.Inventors: TOMASZ GLINKA, Olga Lomovskaya, Keith Bostian, David M. Wallace
-
Publication number: 20120156295Abstract: Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.Type: ApplicationFiled: August 31, 2010Publication date: June 21, 2012Inventors: Prabhu Dutt Mishra, Girish Badrinath Mahajan
-
Publication number: 20120135037Abstract: The present invention is based, in part, on flagellin adjuvant used to enhance immune responses directed against Streptococcus pneumoniae, in particular, to enhance immune responses to polypeptide antigens (e.g., PspA) and capsular polysaccharide from S. pneumoniae. In representative embodiments, the invention provides a fusion protein comprising a flagellin adjuvant and one more polypeptide antigens from S. pneumoniae. In other embodiments, the invention provides a conjugate comprising a flagellin adjuvant covalently linked to a capsular polysaccharide from one or more serotypes of S. pneumoniae. Also provided are compositions comprising the fusion proteins and/or conjugates of the invention as well as immunogenic formulations comprising the inventive fusion proteins, conjugates and/or compositions. The invention also provides methods of producing an immune response against S. pneumoniae and methods of protecting a subject from S.Type: ApplicationFiled: May 27, 2010Publication date: May 31, 2012Inventors: Steven B. Mizel, Sean Reid
-
Publication number: 20120128701Abstract: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.Type: ApplicationFiled: September 9, 2011Publication date: May 24, 2012Inventors: Steven D. Goodman, Lauren O. Bakaletz
-
Publication number: 20120115774Abstract: In some aspects, the present invention provides ultrashort lipopeptides which feature ?-amino acids or ?-peptides and demonstrate antimicrobial activity. Accordingly, some aspects of the present invention provide lipopeptide compositions and methods of making and using the compositions as antimicrobial agents.Type: ApplicationFiled: February 23, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF MANITOBAInventors: George Zhanel, Frank Schweizer
-
STRUCTURAL AND MECHANISTIC BASIS FOR NOVEL COMPOUND BIOSYNTHESIS USING THE 4-ELECTRON HEXOSE OXIDASE
Publication number: 20120108498Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: ApplicationFiled: October 1, 2010Publication date: May 3, 2012Applicant: Academia SinicaInventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu -
Publication number: 20120088671Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSASInventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
-
Publication number: 20120071398Abstract: The present invention relates to peptides comprising amino acids according to Formula I ((X)l(Y)m)n??(I) wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment of microbial infections.Type: ApplicationFiled: November 30, 2011Publication date: March 22, 2012Applicant: NOVABIOTICS LIMITEDInventor: Deborah O'Neil
-
Publication number: 20120058935Abstract: The invention features antimicrobial compositions comprising ?-amyloid peptides, oligomers, and analogs thereof, and methods of using them for the prevention or treatment of an infection.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicant: The General Hospital CorporationInventors: Robert Moir, Rudolph E. Tanzi
-
Publication number: 20120053115Abstract: The present invention relates to novel amide derivatives of the lantibiotic 97518 and their uses. In particular, the present invention describes novel compounds having general formula (II) and their use as antibiotic.Type: ApplicationFiled: November 24, 2008Publication date: March 1, 2012Applicant: Sentinella Pharmaceuticals, Inc.Inventors: Sonia Ilaria Maffioli, Cristina Brunati, Donatella Potenza, Francesca Vasile, Stefano Donadio
-
Patent number: 8097582Abstract: A compound having the general formula (I) R1—NH—CH[(CH2)n—NH—C(NH)—NH2]-CO—R2-A-R4; a pharmaceutical composition comprising the compound and use of the compound for the manufacturing of a medicament for the treatment of a disease such as a microbial disease and/or proliferation/stimulation of eukaryotic cells is described.Type: GrantFiled: May 4, 2007Date of Patent: January 17, 2012Assignee: Neobiotics ABInventors: Anders Grubb, Aftab Jasir, Claes Schalén, Franciszek Kasprzykowski, Regina Kasprzykowska
-
Patent number: 8093217Abstract: Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oligomers and derivatives of these oligomers, hyaluronan binding proteins, antibodies specific for hyaluronan receptors, hyaluronan mimetics, inhibitors of hyaluronan synthesis, and stimulators of hyaluronan degradation.Type: GrantFiled: April 29, 2004Date of Patent: January 10, 2012Assignee: Tufts UniversityInventors: Bryan P. Toole, Suniti Misra, Shibnath Ghatak